Cardio-Oncology Midwest Regional Symposium
Cardio-Oncology Midwest Regional Symposium
批准号:
10391683
负责人:
Tochukwu E.M Okwuosa
金额:
$1.0万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-15 至 2022-08-31
关键词:
AgingArrhythmiaAttentionAutonomic DysfunctionAwarenessCancer Death RatesCancer PatientCancer SurvivorCardiacCardiomyopathiesCardiotoxicityCardiovascular DiseasesCardiovascular systemCaregiversCause of DeathChemotherapy and/or radiationClinicalDiseaseEarly DiagnosisEducational ActivitiesEventFunctional disorderFutureGeneral PractitionersGrowthHealthHeart Valve DiseasesHeart failureHospitalistsHypertensionImmune TargetingImmunotherapyIschemiaKnowledgeMalignant NeoplasmsMidwestern United StatesMissionMonitorMorbidity - disease rateMyocardial InfarctionMyocardial dysfunctionNational Heart, Lung, and Blood InstituteOncologistOncologyOutcomePatient CarePatientsPericardial body locationPeripheralPharmacistsPopulationPreventionProviderRadiationRadiation therapyResearchRiskRisk FactorsSpecialistSurvivorsTherapeuticTherapeutic AgentsToxic effectTreatment-Related CancerUnited States National Institutes of HealthUpdateVariantVentricular Arrhythmiaadverse outcomeagedarmcancer carecancer riskcancer therapycardiovascular healthcare providerseffective therapyimprovedknowledge basemortalitynew therapeutic targetpreventprogramsroutine careside effectsymposiumtooltreatment strategy
中文摘要
癌症患者/幸存者心血管护理的范例-两年一次的心脏病学会议
英文摘要
Paradigms in Cardiovascular Care of the Cancer Patient/Survivor – Biennial Cardio-
Oncology Midwest Regional Educational Symposium
Abstract
Second to cardiovascular disease (CVD) in the U.S., cancer remains the leading cause of death
in the world. Nonetheless, the overall death rate from cancer has declined, and the number of
cancer survivors has increased as a result of advancements in oncologic treatment, and greater
attention by providers to prevention and surveillance for adverse outcomes. By January 1, 2030,
it is estimated that the population of cancer survivors will increase to more than 22.1 million due
to the growth and aging of the population alone.
CVD is the major cause of morbidity and mortality among cancer survivors, and is considered to
be a major cause of mortality among cancer survivors aged 15 to 39 years old. Many
therapeutic approaches to cancer significantly increase the risk of cardiomyopathy, ischemia,
cardiovascular events (including myocardial infarction and ventricular arrhythmias), and
hypertension.
Cardio-oncology is a nascent field that focuses on preventing adverse cardiovascular outcomes
in patients with active cancer and improving the overall cardiovascular health of cancer
survivors. This involves specific understanding of interactions between cancer and the
cardiovascular system; as well as intrinsic knowledge of cancer therapeutic agents including
chemotherapy, radiation therapy, and newer targeted therapies/immunotherapy. The field of
cardio-oncology is becoming more specialized with constant variations in cancer treatment; and
emphasizes a great need to educate and keep clinician up to date. This is particularly important
for primary doctors and other caregivers that remain peripherally involved in routine care of
cancer patient; and need to be cognizant or aware of cancer therapy(ies) received, short and
long-term side effects, and management strategies.
We propose an educational activity that will provide the latest clinical updates in the treatment of
cardiovascular conditions in an oncology setting. The purpose of this program is to familiarize
primary care providers, hospitalists, oncologists, cardiologists, advanced practice providers,
pharmacists, and trainees, with updated treatment of cardiac conditions seen in cancer patients/
survivors; as well as identify ongoing research to further improve our understanding of cancer
therapy-related cardiovascular dysfunction to further enhance management strategies for the
future. Given the paucity of cardio-oncology specialists in many parts of the U.S., the program
will arm general practitioners with practical tools to promote the prevention and treatment of
CVD as a result of cancer therapy, to help their cancer patients live longer and healthier lives.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金